This article has been updated to include Decode's closing stock price on Thursday.
 
NEW YORK (GenomeWeb News) – Decode Genetics said after the close of the market on Wednesday that it is conducting a review of its long-term business strategy with a goal of sharpening its business focus and selling non-core assets, among other aims.
 
Decode's shares tumbled 34 percent to close at $.25 in Thursday trade on the Nasdaq. Its shares are down more than 90 percent from the beginning of the year.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.